Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 131-140 of 3404 for cancer

Edit search filters
  1. Exercise Preconditioning and Breast Cancer Cardiotoxicity

    Scottsdale/Phoenix, AZ

  2. The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer

  3. A Study to Evaluate Dexamethasone in Reducing Everolimus-Induced Oral Stomatitis in Patients With Cancer

    La Crosse, WI, Eau Claire, WI, Rochester, MN

  4. A Tool for Improving the Shared Decision-making Process in Patients With Non-small Cell Lung Cancer

    Rochester, MN

  5. CJNJ-67652000 and Prednisone for the Treatment of Men With Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutations

    Jacksonville, FL, Rochester, MN, Scottsdale/Phoenix, AZ

  6. Neoadjuvant dual checkpoint blockade with PD1 and LAG-3 inhibition in resectable Non-small cell lung Cancer

    Rochester, MN

  7. Synergy with Grid Therapy and Immune Checkpoint Inhibitors in Stage IV Non-Small Cell Lung Cancer

    Rochester, MN

  8. A Study of Selpercatinib Following Definitive Locoregional Treatment in Participants with Non-small Cell Lung Cancer

    Rochester, MN

  9. A Study Comparing Gemcitabine with or without AZD 1775 in Treating Patients with Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

    Rochester, MN

  10. Minority-inclusive Imaging Biomarker-based End of Therapy Trial for 177Lu-PSMA-617

    Rochester, MN

.

Mayo Clinic Footer